CHD was recently awarded two patents for Composition of Matter for products that have demonstrated, both in vitro and in vivo, the ability to safely eliminate a board range of bacteria, viruses and other pathogens without harming human tissue. Furthermore, CDH's technology has demonstrated the ability to quickly kill even the most resistant pathogens such as MRSA and C. difficile. CHD's first product, brand-named VERIOX, is being developed for a wide variety of global markets including but not limited to skin surface disinfection, medical device coatings and advanced wound care application. CHD is developing novel antimicrobial products that can mitigate or treat the increasing threat of Hospial Acquired Infections.